Skip to content

NeuroOne Medical Technologies Corporation: 10-Q filed 2013-05-15

What NeuroOne Medical Technologies Corporation reported in its quarterly report filed 2013-05-15 (fiscal Q1 2013): 16 published measures, 39 facts as tagged in accession 0001014897-13-000168.

This filing

Form
10-Q (quarterly report)
Filed
2013-05-15
Fiscal period
fiscal Q1 2013
Accession
0001014897-13-000168 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NeuroOne Medical Technologies Corporation filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-03-315,133USD
At 2012-12-311,118USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-03-3122,678USD
At 2012-12-3118,355USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-03-31-17,545USD
At 2012-12-31-17,237USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-3,308USD90
2009-08-20 to 2013-03-31-53,695USD1320
2012-01-01 to 2012-03-31-5,574USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-2,985USD90
2009-08-20 to 2013-03-31-49,017USD1320
2012-01-01 to 2012-03-31-5,519USD91

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2013-01-01 to 2013-03-31406USD90
2009-08-20 to 2013-03-318,920USD1320
2012-01-01 to 2012-03-31147USD91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-03-317,000USD90
2009-08-20 to 2013-03-3154,150USD1320

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2013-01-01 to 2013-03-315,073,000shares90
2012-01-01 to 2012-03-315,073,000shares91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-03-315,133USD
At 2012-12-311,118USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-323USD90
2009-08-20 to 2013-03-31-726USD1320
2012-01-01 to 2012-03-31-55USD91

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-03-3122,678USD
At 2012-12-3118,355USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-01-01 to 2013-03-313,391USD90
2009-08-20 to 2013-03-3159,121USD1320
2012-01-01 to 2012-03-315,666USD91

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2013-01-01 to 2013-03-31406USD90
2009-08-20 to 2013-03-316,152USD1320
2012-01-01 to 2012-03-31147USD91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-03-315,073,000shares
At 2012-12-315,073,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-03-3131,077USD
At 2012-12-3128,077USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-313,391USD90
2009-08-20 to 2013-03-3159,121USD1320
2012-01-01 to 2012-03-315,666USD91

Inspect the source

Entity
NeuroOne Medical Technologies Corporation / CIK 0001500198
Captured
2026-09-20T09:11:29.314Z
SEC response SHA-256
dec08ad6d59f8d84b3a6db4a6ff83df3a276b794fed82089495b0788055433dd

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001500198.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))